Last reviewed · How we verify
Symlin®
Symlin (pramlintide) is an amylin analog that slows gastric emptying, suppresses glucagon secretion, and promotes satiety to reduce postprandial blood glucose excursions in diabetes.
Symlin (pramlintide) is an amylin analog that slows gastric emptying, suppresses glucagon secretion, and promotes satiety to reduce postprandial blood glucose excursions in diabetes. Used for Type 1 diabetes mellitus (adjunct to insulin therapy), Type 2 diabetes mellitus (adjunct to insulin therapy).
At a glance
| Generic name | Symlin® |
|---|---|
| Sponsor | Adocia |
| Drug class | Amylin analog |
| Target | Amylin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Pramlintide mimics amylin, a hormone co-secreted with insulin that regulates postprandial glucose levels through multiple mechanisms: delaying gastric emptying to slow nutrient absorption, inhibiting glucagon secretion to prevent hepatic glucose production, and enhancing satiety to reduce food intake. These combined effects help lower postprandial glucose spikes in patients with type 1 and type 2 diabetes.
Approved indications
- Type 1 diabetes mellitus (adjunct to insulin therapy)
- Type 2 diabetes mellitus (adjunct to insulin therapy)
Common side effects
- Nausea
- Vomiting
- Anorexia
- Hypoglycemia
- Injection site reactions
Key clinical trials
- Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D (PHASE2)
- A Trial to Assess Safety and Efficacy of ADO09 Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus (PHASE1, PHASE2)
- A Trial to Assess a Co-formulation of an Insulin Analog and Pramlintide in Subjects With Type 1 Diabetes Mellitus (PHASE1)
- A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone® Pramlintide Insulin in Patients With Type 1 Diabetes Mellitus (PHASE1)
- A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects (PHASE2)
- A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes (PHASE4)
- A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes (PHASE4)
- An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Symlin® CI brief — competitive landscape report
- Symlin® updates RSS · CI watch RSS
- Adocia portfolio CI